Date Hour Room Track
05th December,2018 9:00-10:30 am Track 1

Why should a human-focused biotech company be interested in the animal health industry? Are there common grounds that can lead to more frequent and fruitful collaborations between animal and human health companies in the future?

Today, it is obvious that the animal health industry offers a clear value proposition to human biotechnology companies, which can maximise the financial and clinical impact of their assets by leveraging both human and veterinary health.

The physio pathological features of several diseases (cancer, osteoarticular affections, infectious diseases, pain…) are progressively understood as at least common between animal and human. This paves the way to innovative products developed under the sign of a so-called comparative medicine. This panel will encourage a provocative, straightforward and realistic discussion on what each side needs from the other to set up mutual beneficial partnerships.

Sven Arnouts - PROVAXS
Luigi Aurisicchio - Takis Biotech - Evvivax
Michael L. Salgaller - National Institutes of Health (NIH) | National Cancer Institute (NCI) | Technology Transfer Center
Steve Nanchen - ELANCO R&D
Mark Heffernan - Stonehaven Incubate

Continue your tour